Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the overlooked penny stocks to invest in. On January 12, Alec Stranahan, an analyst at Bank of America Securities, maintained a Hold rating on ...
Java Development Kit (JDK) 26, a planned update to standard Java due March 17, 2026, has reached the initial release candidate (RC) stage. The RC is open for critical bug fixes, with the feature set ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
Earlier in January, Recursion Pharmaceuticals updated investors at the JP Morgan Healthcare Conference on its AI-powered drug discovery platform, clinical programs, and collaborations with partners ...
Market open and close ceremonies take place daily at the Nasdaq MarketSite Studio in Times Square and around the globe. Executives from Recursion (Nasdaq: RXRX), a leading clinical stage TechBio ...
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results